Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

An Assay of Measuring Platelet Reactivity Using Monoclonal Antibody against Activated Platelet Glycoprotein IIb/IIIa in Patients Taking Clopidogrel

  • Joo, Seung-Jae (Department of Cardiology, Jeju National University Hospital) ;
  • Choi, Joon-Hyouk (Department of Cardiology, Jeju National University Hospital) ;
  • Kim, Song-Yi (Department of Cardiology, Jeju National University Hospital) ;
  • Kim, Ki-Seok (Department of Cardiology, Jeju National University Hospital) ;
  • Kim, Young Ree (Department of Laboratory Medicine, Jeju National University Hospital) ;
  • Kang, Sung Ha (Department of Laboratory Medicine, Jeju National University Hospital)
  • Received : 2015.03.02
  • Accepted : 2015.04.28
  • Published : 2015.09.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Residual platelet reactivity in patients who are taking clopidogrel is commonly measured with VerifyNow assay, which is based on the principle of light transmission aggregometry. However, to evaluate the residual platelet reactivity, it would be more accurate if the reactivity of platelet glycoprotein (GP) IIb/IIIa is directly monitored. In this study, PAC1, a monoclonal antibody against activated platelet GP IIb/IIIa, was used to measure the residual platelet reactivity. Subjects and Methods: Twenty seven patients with coronary artery disease taking clopidogrel were enrolled. Platelets in whole blood were stained with fluorescein isothiocyanate (FITC)-conjugated PAC1. Mean fluorescence intensity (MFI) and % positive platelets (PP) were measured with flow cytometry, and the binding index (BI; MFI ${\times}$ %PP/100) was calculated. P2Y12 reaction unit (PRU) and % inhibition of VerifyNow assay were also measured in the usual manner. Results: PRU of VerifyNow assay correlated significantly with MFI, %PP, and BI at $10{\mu}M$ (r=0.59, 0.73, and 0.60, respectively, all p<0.005) and $20{\mu}M$ of adenosine diphosphate (ADP; r=0.61, 0.75, and 0.63, respectively, all p<0.005). The % inhibition also correlated significantly with MFI, %PP, and BI at $10{\mu}M$ (r=-0.60, -0.69, and -0.59, respectively, all p<0.005) and $20{\mu}M$ of ADP (r=-0.63, -0.71, and -0.62, respectively, all p<0.005). Conclusion: Direct measurements of the reactivity of platelet GP IIb/IIIa were feasible using PAC1 and flow cytometry in patients taking clopidogrel. Further clinical studies are required to determine the cut-off values which would define high residual platelet reactivity in patients on this treatment protocol.

Keywords

References

  1. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2014;130:2354-94. https://doi.org/10.1161/CIR.0000000000000133
  2. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/ American Heart Association task force on practice guidelines. Circulation 2013;127:529-55. https://doi.org/10.1161/CIR.0b013e3182742c84
  3. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011;124:2574-609. https://doi.org/10.1161/CIR.0b013e31823a5596
  4. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007;50:1822-34. https://doi.org/10.1016/j.jacc.2007.07.051
  5. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426-35.
  6. Brar SS, ten Berg J, Marcucci R, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011;58:1945-54. https://doi.org/10.1016/j.jacc.2011.06.059
  7. Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004;110:e489-93. https://doi.org/10.1161/01.CIR.0000147228.29325.F9
  8. Geiger J, Teichmann L, Grossmann R, et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005;51:957-65. https://doi.org/10.1373/clinchem.2004.047050
  9. Price MJ. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009;119:2625-32. https://doi.org/10.1161/CIRCULATIONAHA.107.696732
  10. Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303:754-62. https://doi.org/10.1001/jama.2010.181
  11. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003;23:945-52. https://doi.org/10.1161/01.ATV.0000066686.46338.F1
  12. Joo SJ. Mechanisms of platelet activation and integrin ${\alpha}II{\beta}3$. Korean Circ J 2012;42:295-301. https://doi.org/10.4070/kcj.2012.42.5.295
  13. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb. IIIa complex during platelet activation. J Biol Chem 1985;260:11107-14.
  14. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
  15. Abrams CS, Ellison N, Budzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet-derived microparticles in humans. Blood 1990;75:128-38.
  16. Harder S, Klinkhardt U, Graff J, et al. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests. Thromb Res 2001;102:39-48. https://doi.org/10.1016/S0049-3848(01)00223-7
  17. Furman MI, Kereiakes DJ, Krueger LA, et al. Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention. Am Heart J 2003;145:e6.
  18. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL 3rd, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol 2004;43:2319-25. https://doi.org/10.1016/j.jacc.2003.12.055
  19. Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome - fact and fiction. Thromb Haemost 2011;106:191-202. https://doi.org/10.1160/TH11-01-0040
  20. Price MJ, Berger PB, Teirstein PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011;305:1097-105. https://doi.org/10.1001/jama.2011.290
  21. Xiao Z, Théroux P. Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. J Am Coll Cardiol 2004;43:1982-8. https://doi.org/10.1016/j.jacc.2003.10.071
  22. Cayla G, Macia JC, Rabesandratana H, et al. Flow cytometric assessment of vasodilator-stimulated phosphoprotein: prognostic value of recurrent cardiovascular events after acute coronary syndromes. Arch Cardiovasc Dis 2008;101:743-51. https://doi.org/10.1016/j.acvd.2008.10.004
  23. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay. J Thromb Haemost 2010;8:351-9. https://doi.org/10.1111/j.1538-7836.2009.03699.x

Cited by

  1. Detection of Sepsis in Platelets Using MicroRNAs and Membrane Antigens vol.12, pp.12, 2021, https://doi.org/10.3390/genes12121877